

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
 Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
**Patient Preferred Location:** \_\_\_\_\_

## DIAGNOSIS & CLINICAL INFORMATION

<ICD 10 CODE REQUIRED>

**ICD 10 Code (PROVIDE COMPLETE CODE)**

**DERMATOLOGY**

L40.5 \_\_\_\_\_ Psoriatic Arthritis/Arthropathy  
 L40. \_\_\_\_\_ Psoriasis

**GASTROENTEROLOGY**

K50.0 \_\_\_\_\_ Crohn's Disease, Small Intestine  
 K50.1 \_\_\_\_\_ Crohn's Disease, Large Intestine  
 K50.8 \_\_\_\_\_ Crohn's Disease, Small & Large Intestine  
 K50.9 \_\_\_\_\_ Crohn's Disease, Unspecified

K51.8 \_\_\_\_\_ Other Ulcerative Colitis, Chronic  
 K51.5 \_\_\_\_\_ Left Sided - Ulcerative Colitis, Chronic  
 K51.0 \_\_\_\_\_ Universal Ulcerative Pancolitis, Chronic  
 K51.9 \_\_\_\_\_ Ulcerative Colitis, Unspecified  
 K60.3 Anal Fistula  
 K63.2 Fistula of Intestine

**RHEUMATOLOGY**

M05. \_\_\_\_\_ Rheumatoid Arthritis, w/ Rheumatoid Factor  
 M06. \_\_\_\_\_ Rheumatoid Arthritis, w/o Rheumatoid Factor  
 L40.5 \_\_\_\_\_ Psoriatic Arthritis/Arthropathy  
 M45. \_\_\_\_\_ Ankylosing Spondylitis  
 D86.0 Sarcoidosis of the Lung

**OTHER:** \_\_\_\_\_

**REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.**

**LAB RESULTS: Include Negative Hepatitis B within 3 years and Negative TB within 12 months.**

## PRESCRIPTION

**Pre-Medications**

Acetaminophen: 650 mg PO	Famotidine: 20 mg PO
Cetirizine: 10 mg PO	Methylprednisolone: 125 mg SIVP
Diphenhydramine: 25 mg PO	Other: _____
Diphenhydramine: 25 mg IVP	

**Lab Orders+**

*Required:* Negative TB, annually

**+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider.**

**Drug**

Remicade (Infliximab) OR Biosimilar as dictated by patient's insurance\*  
 \* **Medix Infusion will determine appropriate product based upon benefit investigation**

OR

Infliximab product \_\_\_\_\_ (DO NOT SUBSTITUTE)

Infuse in 250 mL of 0.9% NS over at least 2 hours via pump with 0.2-micron filter. Doses > 1000 mg need total volume of 500 mL.  
 Medix Infusion offers Infliximab at a reduced infusion time, beginning on the 4th and subsequent infusions, to patients who qualify and consent.

**Loading Dose: (SELECT ONE)**

**IV:** Infuse 3 mg/kg at weeks 0, 2, and 6  
**IV:** Infuse 5 mg/kg at weeks 0, 2, and 6  
**IV:** Infuse \_\_\_\_\_ mg or \_\_\_\_\_ mg/kg at weeks 0, 2, and 6

**MEDIX USE ONLY**

Product to be used:  
 Remicade  
 Avosla  
 Inflectra  
 Renflexis

**Maintenance: (SELECT ONE)**

**IV:** Infuse 3 mg/kg every 8 weeks for one year  
**IV:** Infuse 5 mg/kg every 8 weeks for one year  
**IV:** Infuse \_\_\_\_\_ mg or \_\_\_\_\_ mg/kg every \_\_\_\_\_ weeks for one year

In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reaction protocol.

**Post Treatment Observations:** The patient is observed for 30 minutes following the first infusion.

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_  
 Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
 Supervising Physician: \_\_\_\_\_ (If Applicable)  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_